Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Comment by PoorOpinionon May 31, 2018 1:10pm

166 Views

Post# 28106403

RE:RE:RE:RE:Pretty bizarre stuff

Balsbuster wrote: IMO this is standard convertable deal hedging. i typically don't assume that the new convert buyers are interested in the equity. They are interested in the yield and take on a hedge bu shorting the stock to protect them from loss due to a decline in the stock price. Typcially this takes a few days to work out, but may be longer since this deal has a 3 week window to it.

https://www.investopedia.com/terms/c/convertible-hedge.asp

So I asked this before about when thera might start paying a dividend, SPCEO responded better all the cash goes into growth which makes sense, but it must happen someday. We talking not in next 3 years, 5years, 10 years???

Bullboard Posts

Changing Europe’s dependency on HREE from China